Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis (Q41939253)

14 October 2017

title

Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1455196

28 September 2022

R. Eliakim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1455196

28 September 2022

F. Karmeli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1455196

28 September 2022

M. Chorev

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1455196

28 September 2022

E. Okon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1455196

28 September 2022

D. Rachmilewitz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1455196

28 September 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1455196

28 September 2022

publication date

1 November 1992

1 reference

Scandinavian Journal of Gastroenterology

14 October 2017

published in

1 reference

14 October 2017

1 reference

14 October 2017

1 reference

14 October 2017

page(s)

968-972

1 reference

Recent developments in "nonspecific" inflammatory bowel disease (first of two parts).

14 October 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Increased prostaglandin production in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Advances in drug therapy for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Comparative trial of sulphasalazine and oral sodium cromoglycate in the maintenance of remission in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Comparative trial of sodium cromoglycate enemas with prednisolone enemas in the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Radioimmunological assay of prostaglandin synthetase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Is N-acetylation of 5-aminosalicylic acid reversible in man?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365529209000172

10.3109/00365529209000172

21 January 2018

Identifiers

DOI

1 reference

14 October 2017

1 reference